Committees & Working Groups

Consortium for Pediatric Cellular Immunotherapy

Home › About › Committees & Working Groups

Committees & Working Groups

Steering Committee

Catherine Bollard, MBChB, MD, Chair

Bio

Catherine Bollard, MBChB, MD

Catherine Bollard, MBChB, MD, is the Director of the Center for Cancer and Immunology Research at the Children’s National Research Institute, Director of the Program for Cell Enhancement and Technologies for Immunotherapy and an Attending Physician within the Division of the Blood and Marrow Transplantation. In addition, she is a Professor of Pediatrics and Microbiology, Immunology and Tropical Medicine at the George Washington University and is the ACD for Translational Research and Innovation within the George Washington Cancer Center. In these roles, Dr. Bollard leads clinical and research efforts to fight cancer and other inflammatory diseases by strengthening the immune system using adoptive cell therapy. As a past president of the International Society of Cellular Therapy, and the current president of the Foundation for the Accreditation for Cellular Therapy (FACT) she is a distinguished hematologist, immunologist and immunotherapist, working to develop cell and gene therapies for patients with cancer and underlying immune deficiencies.

Rebecca Gardner, MD

Michael C. Jensen, MD

Bio

Michael C. Jensen, MD

Michael C. Jensen, MD, is the Vice President and Chief Therapeutics Officer, Seattle Children’s Health System. He is an internationally recognized leader in the field of CAR T cell cancer immunotherapy with over 20 years of experience in the research and clinical translation of this therapeutic modality. He has focused on the applications to childhood cancers. Dr. Jensen graduated from the University of Pennsylvania School of Medicine and then completed training in Pediatric Hematology and Oncology at the University of Washington(UW)/Fred Hutchinson Cancer Research Center (FHCRC) with a focus on the immunobiology of tumor-specific T-cells. In 2010, Dr. Jensen returned to Seattle and joined the University of Washington School of Medicine faculty as a Professor of Pediatrics and Adjunct Professor of Bioengineering, and was the founding director of the Ben Towne Center for Childhood Cancer Research at Seattle Children’s Research Institute.

Julie R. Park, MD

Bio

Julie R. Park, MD

Julie R. Park, MD, is Full Member and Chair, Department of Oncology at St. Jude Children’s Research Center and Associate Director of Translational Research in the St. Jude Comprehensive Cancer Center. Dr. Park’s research is focused on translating laboratory discoveries to improve the survival of children with cancer. She previously led the development and implementation of first in human/first in child cellular therapy at Seattle Children’s Therapeutics and is now collaborating with Bone Marrow Transplant and Cell Therapy at St. Jude to expand efforts for novel cellular therapy. She is past chair of the Children’s Oncology Group Neuroblastoma Scientific Committee, and currently the Scientific Lead for the New Approaches to Neuroblastoma Therapy consortia.

Bonnie W. Ramsey, MD

Bio

Bonnie W. Ramsey, MD

Bonnie W. Ramsey, MD, is an Professor Emeritus in the Department of Pediatrics at the University of Washington School of Medicine in Seattle, Washington. She is a pediatric pulmonologist and clinical scientist with over 40 years of experience in translational research and therapeutic development in the field of cystic fibrosis (CF). She was a lead investigator for development of key therapies in CF including inhaled tobramycin, dornase alpha, and ivacaftor. She has been acknowledged for her contributions to CF including the Paul D’Sant Agnese Award (1998) , the Lifetime Achievement Award (2013) and the Talamo Award in 2022 from the Cystic Fibrosis Foundation (CFF), the Lifetime Achievement Award from the American Thoracic Society (2014), elected to the National Academy of Medicine in 2015, and received the Warren Alpert Foundation Prize (2018). She developed and led the CFF Therapeutics Development Network (TDN) from 1998 to 2015; the largest clinical trials network focused on CF therapies in the world. She worked with Dr. Julie Park to develop the CPCI network for patients receiving cellular immunotherapy based upon the organizational structure of the TDN and continues to serve as the co-PI.

Michael R. Verneris, MD

Bio

Michael R. Verneris, MD

Michael R. Verneris, MD is a Professor of Pediatrics and is the Director of Blood and Marrow Transplantation and Cellular Therapy Program at Colorado Children’s Hospital. In addition, he is the co-director of the Tumor Host Interactions (THI) program that the University of Colorado Cancer Center. He is also the Scientific and Medical Director of the Cellular Therapy Operations Program (CTOP) at the University of Colorado. He also oversees a NIH-funded laboratory that investigates NK and T cells redirected to malignant diseases.

Mark C. Walters, MD

Bio

Mark C. Walters, MD

Mark C. Walters, MD, is the Jordan Family Director of the Blood and Marrow Transplantation Program at UCSF Benioff Children’s Hospital, Oakland and professor and Chief, Hematology division in the Department of Pediatrics at UCSF School of Medicine. He is Program Director of the California Institute of Regenerative Medicine alpha stem cell clinic at UCSF. Dr. Walters received his A.B. with honors in Genetics from the University of California, Berkeley and his MD from the University of California, San Diego. He completed pediatric residency training at the University of Washington and hematology/oncology fellowship training at the University of Washington and the Fred Hutchinson Cancer Research Center in Seattle. He was a junior faculty member in Seattle before matriculating to Oakland in 1999. He has been active in cooperative clinical transplantation trials and has led several NIH-supported investigations of hematopoietic cell transplantation for sickle cell anemia and thalassemia. He has authored or co-authored a number of publications with a focus on hematopoietic cell transplantation for hemoglobin disorders, and he has a research interest in extending transplantation to young adults with hemoglobin disorders and other novel cellular therapies for non-malignant hematological disorders. Currently, research interests are focused on genomic editing and gene addition therapies as a strategy to extend curative therapy in all patients who inherit a clinically significant hemoglobinopathy.

Alan S. Wayne, MD

Bio

Alan S. Wayne, MD

Alan S. Wayne, MD, serves as Director of the Cancer and Blood Disease Institute at Children’s Hospital Los Angeles, Head of the Division of Hematology-Oncology in the Department of Pediatrics, Associate Director for Pediatric Oncology at the USC Norris Comprehensive Cancer Center and Professor of Pediatrics and Medicine at the Keck School of Medicine, University of Southern California. In these roles, he oversees all research, treatment, prevention and education programs in pediatric hematology, oncology and hematopoietic stem cell transplantation within these institutions. Dr. Wayne’s primary research efforts are directed towards the development of new treatment approaches for leukemias and lymphomas with a focus on relapsed/refractory acute lymphoblastic leukemia. He develops and conducts collaborative laboratory, translational and clinical investigations, including bench-to-bedside development of targeted, immune-based and cellular therapies. He serves as the Medical Director of the Therapeutic Advances in Childhood Leukemia/Lymphoma (TACL) Consortium, a multinational clinical trials group that conducts Phase I and II trials. He is also an international leader in the area of post-transplant relapse of hematologic malignancies, with the primary aim to study the biology, prevention and treatment of relapse after hematopoietic stem cell transplant.

External Advisory Board

Stephen Gottschalk, MD

Leslie Kean, MD

Michael Konstan, MD

Biorepository Working Group

Jennifer Cotter, MD

Bio

Jennifer Cotter, MD

Jennifer Cotter, MD, is an Assistant Professor of Clinical Pathology at Keck School of Medicine of USC and Director of the Pediatric Research Biorepository at Children’s Hospital of Los Angeles and Norris Cancer Center of USC. Dr. Cotter is a pediatric neuropathologist at Children’s Hospital Los Angeles. She is interested in process improvements in pathology and laboratory medicine to enhance support of clinical and translational research. Her current focus is biorepository infrastructure development, with a goal to facilitate data sharing and enhance the value of existing biospecimen repositories.

Anushree Datar

Amy Hont, MD

Bio

Amy Hont, MD

Amy Hont, MD, is an attending oncologist at Children’s National Hospital, a member of the Center for Cancer and Immunology Research, and an Assistant Professor of Pediatrics. Dr. Hont specializes in immunotherapy for high-risk malignancies, focusing on solid tumors. Her research focuses on development of novel therapeutics for pediatric cancer utilizing adoptive cell therapy, including pre-clinical and translational studies to optimize the efficacy and safety of these products for pediatric patients.

Wenjun Huang, PhD

Bio

Wenjun Huang, PhD

Wenjun Huang, PhD, is a data scientist in the integrated data science group at Seattle Children’s Therapeutics (Seattle, WA) and a member of the Biorepository Working Group within the Consortium of Pediatric Cellular Immunotherapy (CPCI). He collaborates closely with the scientific and operational team that analyzes key biologic correlative samples collected from pediatric cancer patients worldwide. Dr. Huang is also a key member in the development team for the scientific research data platform, LabKey, at Therapeutics. His work supports the ever-growing amount of correlative sample data to be tracked, stored, and shared with internal and external stakeholders.

Kimberly Jordan, PhD

Monica Mendez

Bio

Monica Mendez

Monica Mendez is the Manager of the Center for Pathology Research (CPRS) in the Department of Pathology and Laboratory medicine at Children’s Hospital Los Angeles. In her role Monica enables timely and equitable access to high quality histology, biospecimens and informatics that can link research data with longitudinal clinical data, resulting in the sharing of biospecimens and data within the pediatric research community locally and nationally.

Angela Minic, MS

Julie Saba, MD, PhD

Bio

Julie Saba, MD, PhD

Julie Saba, MD, PhD, is Professor of Pediatrics in the Hematology/Oncology Division at the UCSF School of Medicine, where she holds the John and Edna Beck endowed Chair in Pediatric Cancer Research and is the Director of the Swim Across America National Laboratory. Dr. Saba is a board certified pediatric oncologist who directs a basic and translational research laboratory at UCSF’s Benioff Children’s Hospital Oakland campus. The scientific focus of her research is the role of sphingolipid signaling in health and disease. Dr. Saba established the first UCSF Benioff Children’s Hospital Oakland Pediatric Tissue Bank and currently serves on the tissue bank’s Scientific Advisory Board.

Keri Toner, MD

Bio

Keri Toner, MD

Keri Toner, MD. is an attending physician in the Leukemia and Lymphoma Program, Division of Blood and Marrow Transplant and CAR-T program at Children’s National. She is an Assistant Professor at GW University School of Medicine and Health Sciences and her research interests include evaluating immunotherapies for high-risk hematologic malignancies.

cGMP Working Group

Christopher T. Brown, Co-Lead

Bio

Christopher T. Brown, Co-Lead

Christopher T. Brown is the Director of GMP Cell Production within the Therapeutic Cell Production Core, Seattle Children’s Therapeutics’ GMP manufacturing facility. He leads the facility’s manufacturing/process development team and played a key role in its initial design, stand-up, and further development over the past decade. He has more than twenty years of experience in the manufacturing of cellular products for phase 1 and 2 clinical trials. He joined Seattle Children’s Research Institute from the Fred Hutchinson Cancer Research Center in 2010, where he oversaw a team responsible for performing clinical production in a clean room facility. He also sits on Seattle Children’s Institutional Review Board. He holds a BA from Carleton College.

Stephanie Mgebroff, Co-Lead

Bio

Stephanie Mgebroff

Stephanie Mgebroff is the Director of GMP Quality Control within the Therapeutic Cell Production Core, Seattle Children’s Therapeutics’ GMP manufacturing facility. She oversees the Quality Control Program , ensuring that therapeutic cell products are safe and meet pre-established specifications prior to being released to the clinical team. Upon joining SCRI, she played a key role in development of the TCPC core infrastructure and standard procedures, including quality control policy development and implementation. Mgebroff has over 14 years of cell therapy and protocol development experience. Prior to joining Seattle Children’s in 2011, she worked at both the Fred Hutchinson Cancer Research Center’s cellular processing facility and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins School of Medicine. She holds a BS, Biology, from Gonzaga University and MSc in Biotechnology from Johns Hopkins University.

Mohamed Abou-El-Enein, MD, PhD, MSPH

Bio

Mohamed Abou-el-Enein, MD, PhD, MSPH

Mohamed Abou-el-Enein, MD, PhD, MSPH, is Associate Professor of Clinical Medicine (Clinical Scholar) in the Department of Medicine, Keck School of Medicine of USC and the inaugural Executive Director of the Joint USC/CHLA Cell Therapy Program. He is also the Director of the cGMP facility at CHLA and the new unit under construction at USC. Dr. Abou-el-Enein is a nationally and internationally recognized expert in planning and executing clinical development programs, designing and operating academic GMP facilities, and in translating cell and gene therapy products from preclinical stage to clinical applications. His research focuses on improving the design of Chimeric Antigen Receptor T cells (CAR T cells) to specifically target diverse solid tumors and facilitate off-the-shelf administration through development of allogeneic CAR T cells.

Julie Annis

Bio

Julie Annis

Julie Annis, MLS(ASCP)CM, has worked at Children’s Hospital Los Angeles since 2013. She is the Manager of Laboratory Operations for Children’s Hospital Los Angeles Cellular Therapy & Transplantation Laboratory (TCTL). The TCTL is responsible for processing all autologous and allogenic blood and marrow stem cell products, cord blood products, and processing all clinical research related cell therapy products. Julie is dedicated to keeping the laboratory at the forefront of developing research. Specific programs include: Cell Therapy with open protocols for CAR T-cells, Immunotherapy, Alternative donor transplantation—haploidentical transplantation via TCRab/CD19 depletion. Julie also acts as a liaison and processing technician in the CHLA GMP Facility. The GMP facility consists of a 1,500 square foot facility consisting of six rooms, including class 10,000 (ISO 7) rooms. The GMP’s most recent activities include a process for production of Viral Specific T-Cells. Julie is a contributing member of Consortium for Pediatric Cellular Immunotherapy. As part of the consortia, her team recently published in Cytotherapy Journal. Julie is currently training as a Foundation for Accreditation on Cellular Therapy (FACT) inspector for cellular therapy laboratories.

Amaia Cadinanos-Garai

Bio

Amaia Cadinanos-Garai

Amaia Cadinanos-Garai is the Associate Director of Quality Control & Analytical Development at the USC/CHLA Cell Therapy Program. She is responsible for the overall QC development for product testing and release. She holds a Biochemistry degree from University of Navarra, Spain and an MRes in Biomedical Research from Imperial College London. She joined University College London’s CAR T-cell program in 2019 to work in the development of novel CAR T-cell approaches. She joined USC in 2022. She has broad experience in the process development, manufacturing, and quality control of multiple autologous and allogeneic CAR T-cells.

Jonathan Esensten, MD, PhD

Bio

Jonathan Esensten, MD, PhD

Jonathan Esensten MD, PhD, is Assistant Adjunct Professor in the Department of Laboratory Medicine at the University of California, San Francisco. He leads an experimental cellular therapy process development and manufacturing group. His group focusses on improving techniques for manufacturing T cell based therapies for patients with autoimmune disease, solid organ transplant, and cancer. He is co-director of the clinical Regulatory T Cell Manufacturing Group. He is also Medical Director of the UCSF HICTF and GMP Facility. He completed residency in clinical pathology and fellowship in transfusion medicine and blood banking at UCSF.

Patrick Hanley, PhD

Bio

Patrick Hanley, PhD

Patrick Hanley, PhD, is an associate research professor of pediatrics and Chief and Director of the Cellular Therapy Program at Children’s National Hospital. He oversees processing for standard of care stem cell transplantation as well as the development, manufacture, and testing of novel cellular therapies and is responsible for seeking partnerships and commercialization of promising cell and gene therapies. Trained as an Immunologist, Dr. Hanley has an extensive background and interest in cellular therapy and is passionate about improving regulations for cellular therapy, training the next generation of cell therapists, and facilitating the translation of new therapeutics. Over the past 15 years he has helped to translate more than 25 cell therapy protocols – ranging from mesenchymal stromal cells to cord blood virus-specific T cells and tumor-associated antigen specific T cells – into the clinic.

Dr. Hanley serves on the board of directors and as the chair of the education committee of the Foundation for the Accreditation of Cellular Therapy (FACT) and is an active cellular therapy and cord blood inspector. He co-founded and served as the inaugural co-chair of the Early Stage Professionals committee and currently serves as the co-chair of the Immuno-Gene Therapy committee of the International Society of Cell and Gene Therapy (ISCT). He is the commissioning editor of the journal Cytotherapy and he serves on the editorial boards of the journals Cytotherapy, Frontiers in Immunology and Immunotherapy, and Molecular Therapy: Methods and Clinical Development. In 2017, along with Drs Catherine Bollard and Russell Cruz, he founded Mana Therapeutics, a biotech company aimed at educating immune cells and eliminating cancer. In his free time he enjoys playing soccer, cooking, and traveling.

Catherine Lindgren

Bio

Catherine Lindgren, Co-Lead

Catherine Lindgren, Senior Director of the Therapeutic Cell Production Core/Quality Assurance at Seattle Children’s is responsible for directing the manufacturing, and quality control operations of the TCPC and ensuring that compliance to strict quality assurance parameters are met. She has more than 35 years of laboratory research experience moving promising new discoveries from the research bench into human clinical cancer research trials, and over 25 years’ experience in GMP quality assurance, overseeing the manufacturing and release of therapeutics for cell-based clinical trials. She holds a BS from Washington State University and certification in biomedical regulatory affairs from the University of Washington.

Chase Daniel McCann, PhD

Matthew Seefeldt

Bio

Matt Seefeldt

Matt Seefeldt is an entrepreneurial scientist with extensive leadership and experience in building start-up biotechnology companies in the cell therapy and protein biologics space. With his expertise in protein chemistry and business management, Matt both developed a Phase III protein biologic (BaroFeron) and commercialized an enabling protein refolding manufacturing technology. Both these technologies were developed from research he conducted during his doctoral studies at the University of Colorado, during which he learned to bootstrap start-up biotechnology companies from the ground up. Since 2015, Matt has employed his technical expertise and start-up experience at the Gates Biomanufacturing Facility (GBF), an academic contract manufacturing organization, specializing in Cell Therapy and Protein-based Phase I biologics. As the third employee hire at the facility, Matt assisted in building out the infrastructure, installing quality systems, and managing both the Protein and Cell Therapy cGMP manufacturing groups as the GBF expanded to a 40-employee organization. Well versed in all phases of biologics manufacturing, Matt developed eight processes that have been submitted as investigation new drugs (INDs). As the Executive Director of the GBF, Matt provides operational leadership and vision to technical innovation and clinical trial support, with the ultimate goal of establishing Colorado as a leader in cell and protein manufacturing and training.

Abeer Shibli, MT

Sandeep Srivastava, PhD

Bio

Sandeep Srivastava, PhD

Sandeep Kumar Srivastava, PhD, is Cellular Therapy Laboratory Lead (CTL Lead, Process Development) at Cellular Therapy Laboratory, Centre for Cancer and Immunology Research, Children’s National Hospital, Washington DC. He involves in several activities such as performing protocol development, process development studies, product validations and cellular therapy product manufacturing to include novel cellular therapy products for FDA-approved investigational new cancer drug (IND) applications using current Good Manufacturing Practices (cGMP) and Good Tissue Practices (GTP).

Jay Tanna, MS, RAC

Bio

Jay Tanna, MS, RAC

Jay Tanna, MS, RAC, is a Quality Assurance Manager in Cellular Therapy Laboratory at Children’s National Hospital (CNH). In this role, he leads the quality system development and implementation and provides support to various investigator initiated and industry sponsored clinical trials at CNH. Prior to CNH, he held a quality assurance position at Memorial Sloan Kettering Cancer Center where he was working with investigators for writing SOPs, reviewing and releasing of products, and developing quality systems for their manufacturing activities. He holds a Master of Science degree in Pharmaceutical Manufacturing and has a Regulatory Affairs Certification from the Regulatory Affairs Professional Society.

Chandresh Undhad

Alix Vaissié

Bio

Alix Vaissié, PharmD, PhD

Alix Vaissié, PharmD, PhD, is the Associate Director of cGMP Operations of the USC/CHLA Cell Therapy Program in Los Angeles, California. She has more than 5 years of experience developing manufacturing processes for cell-based products based on cGMP design considerations.

Coordinating Center

Elisabeth Alleman

Shasank Chennupati

Karin Cilluffo

Liz Gruber

Bio

Liz Gruber

Liz Gruber serves as the Program Manager for the Consortium. In this role, she provides program/project management and communications support to the Consortium’s many committees and working groups as well as the Program Directors/Principal Investigators. In addition, Liz is a Program Manager with Seattle Children’s Therapeutics where she focuses on business operations functions like IT, HR, and Communications.

Zahid Hossain

Wendy Leisenring, ScD

Matthew MacQuivey

Rita Murphy

Prabha Narayanswamy

Bio

Prabha Narayanswamy

Prabha Narayanaswamy, B.Tech, MS, is the Supervisor for the Statistical Programming group at Integrated Data Sciences (IDS). She holds a bachelor’s in biotechnology and a master’s degree in Biostatistics. She works closely with the Clinical Development Group in effectively utilizing data from the clinical trials managed by Seattle Children’s Therapeutics. She is responsible for the data quality and assists with programming and creating data tables for Data Monitoring Committee reports, IND Annual Reports, and Investigator’s brochure reports. The Stats group is also responsible for handling data requests and data analysis.

Thomas Roberts

Kristy Seidel

Vicky Wu, PhD

Bio

Vicky Wu, PhD

Qian “Vicky” Wu, PhD, is an Assistant Professor of Clinical Biostatistics in Clinical Research Division at Fred Hutchinson Cancer Center. Vicky has been working as the lead biostatistician for many CAR-T immunotherapy trials at Seattle Children’s Hospital. Vicky’s research focuses on statistical genetics, biomarker analysis, precision medicine, and trial design. Most of her work is related with CAR-T cell immunotherapy studies. Her recent project is to use appropriate statistical methods to identify prognostic/predictive biomarkers associated with different clinical outcomes. It motivated from a CAR-T trial and can be applied to solve a general clinical question: how to develop a risk score using multiple biomarkers? She has developed several R tools, including CNVtest, ChIPtest, Spacelog, and a user-friendly R Shiny tool SampleN for sample size/power calculation and protocol writing.

Correlative Working Group

Hisham Abdel-Azim, MD, MS

Bio

Hisham Abdel-Azim, MD, MS

Hisham Abdel-Azim, MD, MS, is Associate Professor, Division of Hematology/Oncology-Transplant and Cell Therapy at the University of Southern California, Keck School of Medicine and Children Hospital Los Angeles, Director of Flow Cytometry/Sorting Lab of the Saban Research Institute and Co-Director of Cell Therapy Laboratory.

Kimberly Jordan, PhD

Patient Advocacy Committee

Anurag K. Agrawal, MD, Chair

Bio

Anurag K. Agrawal, MD

Anurag K. Agrawal, MD is Associate Professor of the Division of Oncology in the Department of Pediatrics at the University of California San Francisco School of Medicine. Dr. Agrawal is Director of the Early Phase Oncology and Immunotherapy Program at UCSF Benioff Children’s Hospital Oakland. Dr. Agrawal also serves as the inpatient/outpatient hematology/oncology medical director at Children’s Oakland. Dr. Agrawal’s current scholarship focuses on early phase trials, supportive care, and health disparities for pediatric, adolescent and young adult oncology patients.

Paibel Aguayo-Hiraldo, MD

Bio

Paibel Aguayo-Hiraldo, MD

Paibel Aguayo-Hiraldo, MD, is an Assistant Professor of Clinical Pediatrics in the Cancer and Blood Disorders Institute at Children’s Hospital Los Angeles, at the University of Southern California, Keck School of Medicine. Dr. Aguayo-Hiraldo is the Outpatient Medical Director for the Transplant and Cellular Therapy section, where she leads projects aimed at improving treatment outcomes of post-hematopoietic stem cell transplant complications, including thrombotic microangiopathy and Graft vs. host disease. Given her previous work with immunotherapy/virus-specific T cells, she joined forces with the Consortium for Pediatric Cellular Immunotherapy (CPCI) to understand barriers to care (access to) Immunotherapy as a treatment for pediatric leukemia.

Lourdes Baez Conde, PhD, MPH

Bio

Lourdes Baez Conde, PhD, MPH

Dr. Lourdes Baezconde-Garbanati is Associate Dean for Community Initiatives at the Keck School of Medicine (KSOM) and Associate Director for Community Outreach and Engagement at the Norris Comprehensive Cancer Center at the University of Southern California. She is a tenured Professor in the Department of Population and Public Health Sciences and the Associate Director for the Center for Health Equity in the Americas. Dr. Baezconde-Garbanati is an expert in cancer disparities research with diverse populations, focused on Latino communities. She works in multidisciplinary teams developing culturally specific effective cancer prevention interventions and engaging at risk populations in community-based participatory research. She has pivoted during the pandemic to include COVID misinformation and messaging to reduce disparities in Black and Latino communities using CBPR methods. Two signature programs include Stay Connected Los Angeles and Vaccinate LA., a project with Michele Kipke from the SC CTSI and CHLA.

Dr. Baezconde-Garbanati has been a key member of seven NIH funded research centers including a new Center for which she is the Associate Director with Dr Michael Goran at CHLA -the Southern California Center for Chronic Health Disparities in Latino Children & Families. She has over 200 peer reviewed publications and disseminated her research in community and government outlets. Her innovative and award-winning research has helped to shape the way scientific information is communicated to diverse populations. She has coproduced various films including Tamale Lesson, Rumors and Granny’s Birthday with colleagues in Cinema ( Doe Meyer and Jeremy Kagan) and at the Annenberg School for Communication (Sheila Murphy). Dr. Baezconde-Garbanati has been a voice for inclusion, outreach, and engagement of underserved communities in research to achieve health equity locally, nationally, and internationally.

Tumaini R. Coker, MD, MBA

Bio

Tumaini Rucker Coker, MD, MBA

Tumaini R. Coker, MD, MBA, is Professor of Pediatrics and Chief of General Pediatrics at the University of Washington School of Medicine. Dr. Coker is also Co-Director of the University of Washington’s Child Health Equity Research Program for Post-doctoral Trainees (CHERPP-T) fellowship, a unique two-year training program funded by NICHD where fellows complete a mentored research project in child health equity. As one of the leading scholars in the United States on pediatric primary care delivery design, she leads a successful and extramurally-funded research program on primary care delivery design, with a focus on community-engaged design, adaptation, testing, and dissemination of preventive care delivery models that aim to promote health equity and eliminate health and healthcare disparities for vulnerable populations.

Devan Duenas, MA

Bio

Devan Duenas, MA

Devan Duenas, MA, is a Clinical Research Coordinator at the Treuman Katz Center for Pediatric Bioethics at Seattle Children’s Research Institute. He currently acts as the Managing Editor for the Challenging Cases in Research Ethics series in the American Journal of Bioethics. Mr. Duenas also currently acts as the Coordinator for both the Research Bioethics Consultation Service and the Clinical Research Ethics Consultation Collaborative (CRECC).

Anurekha Gollapudi Hall, MD

On Ho, PhD

Amy Keating, MD

Bio

Amy Keating, MD

Amy Keating, MD, is an Associate Professor of Pediatrics and Clinical Medical Director of the Blood and Marrow Transplant and Cellular Therapeutics Program at the University of Colorado School of Medicine and the Children’s Hospital of Colorado. Dr. Keating is focused on providing new and novel cell therapies to young patients with malignancies and ensuring that all patients have access to these innovative therapies.

Adam J. Lamble, MD

Bio

Adam J. Lamble, MD

Adam J. Lamble, MD, is Assistant Professor in the Department of Pediatrics at the University of Washington School of Medicine and pediatric oncologist at Seattle Children’s Hospital. Dr. Lamble’s clinical and research interests focus on high-risk hematologic malignancies and immune based therapies. He is a member of the Children’s Oncology Group myeloid diseases committee and is currently leading multiple early phase clinical trials for pediatric patients with relapsed hematologic malignancies.

Jonathan M. Marron, MD, MPH

Bio

Jonathan M. Marron, MD, MPH

Jonathan Marron, MD, MPH, is a pediatric oncologist, bioethicist, health services researcher, and educator at Boston Children’s Hospital, Dana-Farber Cancer Institute, and Harvard Medical School. In addition to his clinical and research work, Dr. Marron teaches ethics courses in the Harvard Medical School (HMS) medical school curriculum and the HMS Master’s in Bioethics graduate program (“Introduction to Clinical Ethics” and “Pediatric Bioethics”). He also serves as a Clinical Ethicist at both Boston Children’s and Dana-Farber, in addition to serving as Teaching Faculty at the Harvard Medical School Center for Bioethics. Dr. Marron’s research focuses on the intersection of ethics and decision-making, with a particular interest in pediatric precision cancer medicine and other emerging technologies, using both qualitative and quantitative methodolgies. His recent scholarship has focused on pediatric ethics, ethical issues in genetics/genomics, informed consent, healthcare disparities, and ethical issues related to communication. Dr. Marron is the former chair of the Ethics Committee of the American Society of Clinical Oncology and a current member of the NIGMS Human Genetic Cell Repository Scientific Advisory Committee.

Julie R. Park, MD

Bio